The immune molecular landscape of the B7 and TNFR immunoregulatory ligand-receptor families in head and neck cancer: A comprehensive overview and the immunotherapeutic implications.

Abstract:

:The B7 family and tumor necrosis factor receptor (TNFR) superfamily play a vital role in the T-cell co-stimulatory and co-inhibitory pathways, regulating T-cell activation, tolerance, and exhaustion; therapeutic modulation of these pathways is translated into effective new cancer treatments. Better understanding of the immune molecular landscapes of the B7 and TNFR families would guide head and neck immuno-oncology clinical research. We performed comprehensive molecular profiling of 10 B7 and 6 TNFR family members in head and neck cancer. Over 20% of patients had B7 and TNFR gene alterations. B7 gene amplifications were relatively more common (3-11%) than TNFR gene amplifications (0-5%). Analysis of 496 sequenced samples revealed that all genes were upregulated: B7 and TNFR mRNA were upregulated in 158 cases (> 30%) and 83 cases (∼15%), respectively. B7-H1 (PD-L1) mRNA upregulation was the most common (∼10%). Promoter methylation analysis indicated an epigenetic basis for B7 and TNFR gene regulation (especially B7-H1, which was relatively strongly correlated with promoter methylation). B7-H1 expression was significantly associated with worse overall survival, and its expression was increased in cases with gene amplifications. Human papillomavirus (HPV) status correlated significantly with B7-H1 alterations at genetic level. Almost half (47.1%) of HPV-negative patients had deep or shallow B7-H1 deletion; >90% of HPV-positive patients had diploid, copy number gain, or amplification of B7-H1. This is the first study elucidating the immune molecular landscapes of the B7 and TNFR families in head and neck cancer, providing a potential novel rationale for clinical investigations.

journal_name

Oncoimmunology

journal_title

Oncoimmunology

authors

Chen YP,Zhang J,Wang YQ,Liu N,He QM,Yang XJ,Sun Y,Ma J

doi

10.1080/2162402X.2017.1288329

subject

Has Abstract

pub_date

2017-02-16 00:00:00

pages

e1288329

issue

3

eissn

2162-4011

issn

2162-402X

pii

1288329

journal_volume

6

pub_type

杂志文章
  • Enhanced expression of CD39 and CD73 on T cells in the regulation of anti-tumor immune responses.

    abstract::Synthesis of extracellular adenosine by the ectonucleotidases CD39 and CD73 represents an important pathway of immune suppression in the tumor microenvironment. Using two mouse models (RET transgenic melanoma and Panc02 orthotopic pancreatic adenocarcinoma), we identified an elevated frequency of ectonucleotidase-expr...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2020.1744946

    authors: Shevchenko I,Mathes A,Groth C,Karakhanova S,Müller V,Utikal J,Werner J,Bazhin AV,Umansky V

    更新日期:2020-04-09 00:00:00

  • Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma.

    abstract::Merkel cell carcinoma (MCC) is a rare skin cancer caused by Merkel cell polyomavirus (MCPyV) infection and/or ultraviolet radiation-induced somatic mutations. The presence of tumor-infiltrating lymphocytes is evidence that an active immune response to MCPyV and tumor-associated neoantigens occurs in some patients. How...

    journal_title:Oncoimmunology

    pub_type: 杂志文章,评审

    doi:10.1080/2162402X.2017.1338237

    authors: Schadendorf D,Nghiem P,Bhatia S,Hauschild A,Saiag P,Mahnke L,Hariharan S,Kaufman HL

    更新日期:2017-08-31 00:00:00

  • Glycan-mediated modification of the immune response.

    abstract::Aberrantly glycosylated tumor antigens represent promising targets for the development of anti-cancer vaccines, yet how glycans influence immune responses is poorly understood. Recent studies have demonstrated that GalNAc-glycosylation enhances antigen uptake by dendritic cells as well as CD4+ T-cell and humoral respo...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.23659

    authors: Madsen CB,Pedersen AE,Wandall HH

    更新日期:2013-04-01 00:00:00

  • LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma.

    abstract::Immunotherapy with immune checkpoint molecule-specific monoclonal antibody have obtained encouraging results from preclinical studies and clinical trials, which promoted us to explore whether this kind of immunotherapy could be applicable to head and neck squamous cell carcinoma (HNSCC). Lymphocyte activation gene-3 (...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2016.1239005

    authors: Deng WW,Mao L,Yu GT,Bu LL,Ma SR,Liu B,Gutkind JS,Kulkarni AB,Zhang WF,Sun ZJ

    更新日期:2016-10-07 00:00:00

  • IDH-mutant gliomas harbor fewer regulatory T cells in humans and mice.

    abstract::The metabolic gene isocitrate dehydrogenase 1 (IDH1) is commonly mutated in lower grade glioma (LGG) and secondary glioblastoma (GBM). Regulatory T cells (Tregs) play a significant role in the suppression of antitumor immunity in human glioma. Given the importance of Tregs in the overall framework of designing immune-...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2020.1806662

    authors: Richardson LG,Nieman LT,Stemmer-Rachamimov AO,Zheng XS,Stafford K,Nagashima H,Miller JJ,Kiyokawa J,Ting DT,Wakimoto H,Cahill DP,Choi BD,Curry WT

    更新日期:2020-08-20 00:00:00

  • EBV infection determines the immune hallmarks of plasmablastic lymphoma.

    abstract::Despite recent therapeutic progress, plasmablastic lymphoma (PBL), a distinct entity of high grade B cell lymphoma, is still an aggressive lymphoma with adverse prognosis. PBL commonly occurs in patients with HIV infection and PBL cells frequently express Epstein Barr virus (EBV) genome with type I latency. Occasional...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2018.1486950

    authors: Gravelle P,Péricart S,Tosolini M,Fabiani B,Coppo P,Amara N,Traverse-Gléhen A,Van Acker N,Brousset P,Fournie JJ,Laurent C

    更新日期:2018-07-30 00:00:00

  • The consensus Immunoscore in phase 3 clinical trial (N0147) and impact on patient management decisions.

    abstract::The consensus Immunoscore is a routine assay quantifying the adaptive immune response within the tumor microenvironment. It has a prognostic value that has been confirmed in a phase 3 clinical trial (NCCTG N0147) in stage III colon cancers. Moreover, results from another phase 3 randomized trial revealed the predictiv...

    journal_title:Oncoimmunology

    pub_type: 杂志文章,评审

    doi:10.1080/2162402X.2020.1796003

    authors: Lanzi A,Sinicrope FA,Benson AB,Galon J

    更新日期:2020-07-20 00:00:00

  • Blockade of Tumor-Expressed PD-1 promotes lung cancer growth.

    abstract::Anti-PD-1 immunotherapy is the standard of care for treating many patients with non-small cell lung cancer (NSCLC), yet mechanisms of treatment failure are emerging. We present a case of NSCLC, who rapidly progressed during a trial (NCT02318771) combining palliative radiotherapy and pembrolizumab. Planned tumor biopsy...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2017.1408747

    authors: Du S,McCall N,Park K,Guan Q,Fontina P,Ertel A,Zhan T,Dicker AP,Lu B

    更新日期:2018-01-29 00:00:00

  • Hormesis in cancer immunology: Does the quantity of an immune reactant matter?

    abstract::We recently reported that tumor-directed antibodies could either stimulate, or inhibit, tumor progression, dependent upon the dosage used. The narrow range over which this immune response curve (IRC) occurs is surprising. Here we discuss features of the IRC, the mechanisms identified so far, and the potential clinical...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.29312

    authors: Pearce OM,Läubli H,Bui J,Varki A

    更新日期:2014-06-25 00:00:00

  • Potent immunosuppressive effects of the oncometabolite R-2-hydroxyglutarate.

    abstract::Somatic gain-of-function mutations in isocitrate dehydrogenase (NADP(+)) 1, cytosolic (IDH1) or isocitrate dehydrogenase (NADP(+)) 2, mitochondrial (IDH2) are bona fide oncogenic drivers of acute myeloid leukemia and glioma because the neomorphic enzymes catalyze the synthesis of R-2-hydroxylutarate (R-2-HG), an oncom...

    journal_title:Oncoimmunology

    pub_type: 社论

    doi:10.1080/2162402X.2018.1528815

    authors: Galluzzi L,Kroemer G

    更新日期:2018-10-16 00:00:00

  • Invariant NKT cells: Killers and conspirators against cancer.

    abstract::Although invariant natural killer T (iNKT) cells influence antitumor responses indirectly by secreting cytokines and promoting the cytolytic functions of T and NK cells, we find that iNKT cells mediate direct tumoricidal activity in vitro and significantly inhibit tumor growth in vivo, even in the absence of other cyt...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.27440

    authors: Bassiri H,Das R,Nichols KE

    更新日期:2013-12-01 00:00:00

  • Monocyte-derived dendritic cells: Emerging players in the antitumor immune response.

    abstract::The elicitation of efficient antitumor immune responses requires the optimal activation of tumor-associated dendritic cells (DCs). Our comparison of the effect of various immunostimulatory treatments on DCs revealed that the best predictor of the success of immunotherapy is not the activation of existing DC population...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.26443

    authors: Kuhn S,Ronchese F

    更新日期:2013-11-01 00:00:00

  • Deep immune profiling of ovarian tumors identifies minimal MHC-I expression after neoadjuvant chemotherapy as negatively associated with T-cell-dependent outcome.

    abstract::Epithelial Ovarian cancer (EOC) is the most lethal gynecological malignancy and has limited curative therapeutic options. Immunotherapy for EOC is promising, but clinical efficacy remains restricted to a small percentage of patients. Several lines of evidence suggest that the low response rate might be improved by com...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2020.1760705

    authors: Brunekreeft KL,Paijens ST,Wouters MCA,Komdeur FL,Eggink FA,Lubbers JM,Workel HH,Van Der Slikke EC,Pröpper NEJ,Leffers N,Adam J,Pijper H,Plat A,Kol A,Nijman HW,De Bruyn M

    更新日期:2020-05-13 00:00:00

  • Cell-type specific MyD88 signaling is required for intestinal tumor initiation and progression to malignancy.

    abstract::The signal adapter MyD88, an essential component of Toll-like receptor (TLR) signaling, is important for gut-microbiome interactions. However, its contribution to cancer and its cell-type specific functions are controversially discussed. Therefore, we generated new tissue-specific mouse models and analyzed the clinica...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2018.1466770

    authors: Holtorf A,Conrad A,Holzmann B,Janssen KP

    更新日期:2018-06-11 00:00:00

  • Differential potency of regulatory T cell-mediated immunosuppression in kidney tumors compared to subcutaneous tumors.

    abstract::In many cancers, regulatory T cells (Treg) play a crucial role in suppressing the effector immune response thereby permitting tumor development. Indeed, in mouse models, their depletion can promote the regression of tumors of various origins, including renal cell carcinoma when located subcutaneous (SC). In the presen...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/21624011.2014.963395

    authors: Devaud C,Westwood JA,Teng MW,John LB,Yong CS,Duong CP,Smyth MJ,Darcy PK,Kershaw MH

    更新日期:2014-12-21 00:00:00

  • PD-L1 co-stimulation, ligand-induced TCR down-modulation and anti-tumor immunotherapy.

    abstract::PD-1 engagement on the surface of effector T cells strongly suppresses their cytotoxic function, which constitutes a major obstacle for T cell-mediated anti-tumor activities. Surprisingly, PD-1 is strongly upregulated in T cells, engaging its ligand PD-L1 during antigen presentation. However, our recent published data...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.1.1.17824

    authors: Karwacz K,Arce F,Bricogne C,Kochan G,Escors D

    更新日期:2012-01-01 00:00:00

  • Trial watch: dietary interventions for cancer therapy.

    abstract::Dietary interventions have a profound impact on whole body metabolism, including oncometabolism (the metabolic features allowing cancer cells to proliferate) and immunometabolism (the catabolic and anabolic reactions that regulate immune responses). Recent preclinical studies demonstrated that multiple dietary changes...

    journal_title:Oncoimmunology

    pub_type: 杂志文章,评审

    doi:10.1080/2162402X.2019.1591878

    authors: Lévesque S,Pol JG,Ferrere G,Galluzzi L,Zitvogel L,Kroemer G

    更新日期:2019-04-03 00:00:00

  • Ménage à trois: Sustained therapeutic anti-tumor immunity requires multiple partners in malignant glioma.

    abstract::Glioblastoma is an aggressive primary brain cancer. Given our interest in novel immunotherapies, we have recently shown that inhibiting CTLA-4, PD-L1 and IDO results in a dramatic survival advantage in mice with brain tumors. Our preclinical study supports the rapid translation of this approach into phase I clinical t...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.28927

    authors: Wainwright DA,Lesniak MS

    更新日期:2014-05-15 00:00:00

  • Longitudinal confocal microscopy imaging of solid tumor destruction following adoptive T cell transfer.

    abstract::A fluorescence-based, high-resolution imaging approach was used to visualize longitudinally the cellular events unfolding during T cell-mediated tumor destruction. The dynamic interplay of T cells, cancer cells, cancer antigen loss variants, and stromal cells-all color-coded in vivo-was analyzed in established, solid ...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.26677

    authors: Schietinger A,Arina A,Liu RB,Wells S,Huang J,Engels B,Bindokas V,Bartkowiak T,Lee D,Herrmann A,Piston DW,Pittet MJ,Lin PC,Zal T,Schreiber H

    更新日期:2013-11-01 00:00:00

  • TIE-2 expressing monocytes in human cancers.

    abstract::Tumor-associated macrophages (TAM) are well known as a key player in the tumor microenvironment, which support cancer progression. More recently, a lineage of monocytes characterized by the expression of the TIE-2/Tek angiopoietin receptor identified a subset of circulating and tumor-associated monocytes endowed with ...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2017.1303585

    authors: Turrini R,Pabois A,Xenarios I,Coukos G,Delaloye JF,Doucey MA

    更新日期:2017-03-16 00:00:00

  • A novel facet of tumor suppression by p53: Induction of tumor immunogenicity.

    abstract::Pharmacological reactivation of the p53 tumor suppressor is a promising strategy for anti-cancer therapy due to its high potential to elicit apoptosis or growth arrest in cancer cells. Recently we uncovered the mechanism of activation of the innate immune response by p53 upon its activation by small molecules. ...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.19409

    authors: Li H,Lakshmikanth T,Carbone E,Selivanova G

    更新日期:2012-07-01 00:00:00

  • Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy?

    abstract::The first study demonstrating that human colorectal carcinoma (CRC) is under robust immunosurveillance was published a decade ago. Today, it is clear that CRC patients with Stage III lesions abundantly infiltrated by effector memory T cells have a better prognosis than subjects with Stage I neoplasms exhibiting no or ...

    journal_title:Oncoimmunology

    pub_type: 社论

    doi:10.1080/2162402X.2015.1058597

    authors: Kroemer G,Galluzzi L,Zitvogel L,Fridman WH

    更新日期:2015-06-05 00:00:00

  • Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition.

    abstract::High-risk endometrial cancer (EC) is an aggressive disease for which new therapeutic options are needed. Aims of this study were to validate the enhanced immune response in highly mutated ECs and to explore immune profiles in other EC subgroups. We evaluated immune infiltration in 116 high-risk ECs from the TransPORTE...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2016.1264565

    authors: Eggink FA,Van Gool IC,Leary A,Pollock PM,Crosbie EJ,Mileshkin L,Jordanova ES,Adam J,Freeman-Mills L,Church DN,Creutzberg CL,De Bruyn M,Nijman HW,Bosse T

    更新日期:2016-12-09 00:00:00

  • The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200.

    abstract::PD-L1 expression and regulation by mesenchymal tumor cells remain largely undefined. Here, we report that among different EMT-activated MCF7 human breast cancer cell clones, PD-L1 was differentially upregulated in MCF7 sh-WISP2, MCF7-1001/2101, and MDA-MB-231 cells but not in MCF7 SNAI1 and MCF7 SNAI1-6SA cells. Mecha...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2016.1263412

    authors: Noman MZ,Janji B,Abdou A,Hasmim M,Terry S,Tan TZ,Mami-Chouaib F,Thiery JP,Chouaib S

    更新日期:2017-01-23 00:00:00

  • A PI3K p110α-selective inhibitor enhances the efficacy of anti-HER2/neu antibody therapy against breast cancer in mice.

    abstract::Combination therapies with phosphoinositide 3-kinase (PI3K) inhibitors and trastuzumab (anti-human epidermal growth factor receptor [HER]2/neu antibody) are effective against HER2+ breast cancer. Isoform-selective PI3K inhibitors elicit anti-tumor immune responses that are distinct from those induced by inhibitors of ...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2017.1421890

    authors: Choi JH,Kim KH,Roh KH,Jung H,Lee A,Lee JY,Song JY,Park SJ,Kim I,Lee WS,Seo SK,Choi IW,Fu YX,Yea SS,Park S

    更新日期:2018-01-16 00:00:00

  • Enhancing the clinical coverage and anticancer efficacy of immune checkpoint blockade through manipulation of the gut microbiota.

    abstract::Although anticancer therapy with immune checkpoint blockers has seen unprecedented success, it fails to control neoplasia in most patients and often causes immune-related adverse events (irAEs). Our recent research shows the immunostimulatory and antitumor effects of CTLA-4 blockade depend on distinct Bacteroides spec...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2015.1132137

    authors: Pitt JM,Vétizou M,Gomperts Boneca I,Lepage P,Chamaillard M,Zitvogel L

    更新日期:2016-02-18 00:00:00

  • A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes.

    abstract::The tumor microenvironment is characterized by of high levels of extracellular nucleotides that are metabolized through the dynamic and sequential action of cell surface enzymes (ectoenzymes). These ectoenzymes operate according to their spatial arrangement, as part of (1) continuous (molecules on the same cell) or (2...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.26246

    authors: Horenstein AL,Chillemi A,Zaccarello G,Bruzzone S,Quarona V,Zito A,Serra S,Malavasi F

    更新日期:2013-09-01 00:00:00

  • Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma.

    abstract::Gliomas are lethal brain tumors that resist standard therapeutic approaches. Immunotherapy is a promising alternative strategy mostly developed in the context of glioblastoma. However, there is a need for implementing immunotherapy for grade II/III gliomas, as these are the most common CNS tumors in young adults with ...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2017.1391972

    authors: Dutoit V,Migliorini D,Ranzanici G,Marinari E,Widmer V,Lobrinus JA,Momjian S,Costello J,Walker PR,Okada H,Weinschenk T,Herold-Mende C,Dietrich PY

    更新日期:2017-11-07 00:00:00

  • Pharmacological targeting of peptidylarginine deiminase 4 prevents cancer-associated kidney injury in mice.

    abstract::Renal insufficiency is a frequent cancer-associated problem affecting more than half of all cancer patients at the time of diagnosis. To minimize nephrotoxic effects the dosage of anticancer drugs are reduced in these patients, leading to sub-optimal treatment efficacy. Despite the severity of this cancer-associated p...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2017.1320009

    authors: Cedervall J,Dragomir A,Saupe F,Zhang Y,Ärnlöv J,Larsson E,Dimberg A,Larsson A,Olsson AK

    更新日期:2017-04-20 00:00:00

  • Multiverse of immune microenvironment in metastatic colorectal cancer.

    abstract::The comprehensive analysis of patients with a complete resection of all metastases reveals the heterogeneity of the colorectal metastatic disease and its clinical impact. Complex tumor immune interrelations shape the metastatic landscape, not only in terms of number and size of lesions, or mutational pattern, but also...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2020.1824316

    authors: Van den Eynde M,Mlecnik B,Bindea G,Galon J

    更新日期:2020-09-29 00:00:00